Rapid Micro Biosystems (RPID) Net Income towards Common Stockholders (2020 - 2026)
Rapid Micro Biosystems (RPID) posted Net Income towards Common Stockholders of -$14.3 million for Q1 2026, down 14.23% sequentially from -$12.5 million in Q4 2025, and down 26.74% YoY from -$19.5 million in Q1 2025.
Rapid Micro Biosystems (RPID) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$14.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 26.74% year-over-year to -$14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.1 million (down 11.83% YoY) and the FY2025 annual result came in at -$47.1 million, changed 0.5% from the prior year.
- Net Income towards Common Stockholders eased to -$14.3 million in Q1 2026 per RPID's latest filing, from -$12.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$9.7 million in Q4 2024 and troughed at -$16.4 million in Q4 2022.
- A 5-year average of -$13.0 million and a median of -$13.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 38.56% in 2022, then slipped 29.29% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$16.4 million in 2022, then surged by 32.07% to -$11.2 million in 2023, then rose by 13.48% to -$9.7 million in 2024, then slipped by 29.29% to -$12.5 million in 2025, then slipped by 14.23% to -$14.3 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$14.3 million, -$12.5 million, and -$11.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Rapid Micro Biosystems | 80.98 Mn | 61.21 Mn | 1.21 Mn | -12.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.92 Mn |
| Mar 31, 2026 | -14.28 Mn |
| Dec 31, 2025 | -12.50 Mn |
| Sep 30, 2025 | -11.51 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Mar 31, 2025 | -11.26 Mn |
| Dec 31, 2024 | -9.67 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Jun 30, 2024 | -12.58 Mn |
| Mar 31, 2024 | -13.32 Mn |
| Dec 31, 2023 | -11.17 Mn |
| Sep 30, 2023 | -13.39 Mn |
| Jun 30, 2023 | -14.02 Mn |
| Mar 31, 2023 | -13.89 Mn |
| Dec 31, 2022 | -16.45 Mn |
| Sep 30, 2022 | -16.34 Mn |
| Jun 30, 2022 | -13.09 Mn |
| Mar 31, 2022 | -14.93 Mn |
| Dec 31, 2021 | -14.61 Mn |
| Sep 30, 2021 | -25.23 Mn |